Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Gyre Therapeutics Inc GYRE

Healthcare Biotechnology
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.


NDAQ:GYRE - Post by User

Gyre Therapeutics Inc
Bullboard Posts
User Avatar Image
(10)
•••
Post by MikeTesteron Jan 23, 2025 6:49pm
16 Views
Post# 36417992

Gyre Therapeutics (GYRE): A Diversified Pipeline Tackling Ch

Gyre Therapeutics (GYRE): A Diversified Pipeline Tackling ChSolid play here. GYRE looking interesting with their anti-fibrotic pipeline and strong China market presence. F351 Phase 3 trial for chronic hepatitis B liver fibrosis coming up Q1 2025 could be a major catalyst. Revenue hit $113.5M in 2023, up from $102.3M previous year. No debt, $15.87M cash, and strong liquidity ratio of 3.72. Nintedanib launch in 2025 might help offset potential ETUARY sales decline. Taking a small position and watching closely.BTW, BeyondSPX continues to deliver high quality in-depth analysis on just about every US stock out there, even microcaps, for free. Great resource for DD.                         https://beyondspx.com/article/gyre-therapeutics-gyre-a-diversified-pipeline-tackling-chronic-organ-diseases



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities